Journal of Clinical Oncology
Articles in this Issue
Clinical, pathological, and molecular characteristics of advanced colorectal cancer in younger vs older patients: Results from a Latin American cancer center.
226 Background: Colorectal cancer (CRC) is the third most common malignancy worldwide, with over 1.9 million new cases ann...
Racial demographic reporting in clinical trials supporting NCCN gastric cancer guidelines.
823 Background: Gastric cancer exhibits significant global and racial disparities in incidence and mortality, with higher...
Radiotherapy versus local ablation therapy for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis.
547 Background: Local ablation therapies, including radiofrequency ablation (RFA) and microwave ablation (MWA), are common...
Racial differences in the impact of pre-existing mental health diagnosis on colorectal cancer survival: A single-center retrospective propensity-matched analysis.
45 Background: Racial disparities in colorectal cancer (CRC) epidemiology and mortality have been well documented, with Bl...
Nutritional status, cachexia, and sarcopenia as predictors of mortality in colorectal cancer: A nationwide analysis of the NIS 2016–2022.
51 Background: Malnutrition, cachexia, and sarcopenia are common in colorectal cancer (CRC) and represent overlapping synd...
Efficacy and safety of first-line chemotherapy in elderly patients with advanced biliary tract cancer: A multi-institutional retrospective study.
548 Background: Systemic chemotherapy is standard treatment for advanced biliary tract cancer (BTC); however, prognosis re...
Prognostic value of ctDNA monitoring in patients with resectable pancreatic ductal adenocarcinoma during surveillance.
778 Background: Pancreatic ductal adenocarcinoma (PDAC) has a high recurrence rate, with up to 80% of patients experiencin...
Profiling tumor characteristics and outcomes in colorectal cancers (CRC) from carriers of the recessive MUTYH founders (G396D/Y179C) and the low-penetrance APC founder APC-I1307K.
32 Background: The clinical significance of CRC risk imparted by prevalent recessive variants MUTYH-G396D and Y179C (Cauca...
Integrated penpulimab (a PD-1 inhibitor), anlotinib (an antiangiogenic targeted drug), nab-paclitaxel and gemcitabine as first-line regimen for metastatic pancreatic cancer: A multi-centered, randomized controlled trial (RCT-PAAG).
655 Background: Metastatic pancreatic cancer (mPC) remains one of the deadliest advanced malignant tumors, which features...
Prevalence and clinical profile of inflammatory bowel disease patients with small bowel cancer: A retrospective analysis of National Inpatient Sample data.
484 Background: Small bowel cancer (SBC) accounts for around 3% of all gastrointestinal malignancies, with inflammatory bo...
Molecular analysis to predict the clinical benefit of everolimus in gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).
641 Background: The mammalian target of rapamycin (mTOR) inhibitor everolimus has shown efficacy, particularly in GEP-NETs...
Utility of ctDNA in early switch of first-line mFOLFIRINOX in metastatic pancreatic ductal adenocarcinoma (mPDAC).
TPS799 Background: PDAC has a very poor 5-year survival rate of 13% in the US and is projected to become the second leadin...
BTN1A1 expression as a biomarker for patient selection: Phase 1b IHC analysis and clinical outcomes supporting a biomarker-guided phase 2 trial in colorectal cancer.
TPS281 Background: Metastatic colorectal cancer (CRC) has poor prognosis in patients resistant or intolerant to oxaliplati...
Diffusion-weighted magnetic resonance imaging versus surgical staging in patients with colorectal peritoneal metastases: The multicenter, international, randomized controlled DISCO trial.
15 Background: In patients with colorectal peritoneal metastases (CPM), cytoreductive surgery (CRS) can prolong survival a...
Epidemiological characterization of biliary tract cancer patients from the Spanish RETUD Registry.
503 Background: Biliary tract cancer (BTC) is a heterogeneous group of tumors, including cholangiocarcinoma (intra and ext...
Impact of longitudinal comprehensive distress screening on cancer-related distress and overall survival.
831 Background: Diagnosis and first-course treatment of gastrointestinal malignancies pose multifactorial and evolving str...
Cell-free DNA predictive epigenetic signatures (PSig) for risk stratification of pancreatic ductal adenocarcinoma (PDA) patients on palliative therapy.
743 Background: Reliable predictors of early progression on palliative chemotherapy (PCT) in pancreatic ductal adenocarcin...
Clinical significance of serum tumor marker dynamics during preoperative chemotherapy and hepatectomy for colorectal liver metastases.
204 Background: Surgical resection of colorectal cancer liver metastasis (CRLM) provides the best chance for long-term sur...
Impact of Ca19-9 reduction on resectability and survival in pancreatic cancer patients following neoadjuvant or conversion chemotherapy.
765 Background: Surgical curability in pancreatic cancer remains very limited. It is still unclear how this may change fol...
First-line (1L) trastuzumab deruxtecan (T-DXd) with volrustomig and fluoropyrimidine in patients with HER2-low gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) part 5.
TPS472 Background: T-DXd (6.4 mg/kg), a HER2-directed antibody-drug conjugate, is approved in several countries for patien...
A multi-center phase 1b/2 clinical trial of concurrent administration of fruquintinib and FTD/TPI in patients with previously treated unresectable metastatic colorectal cancer and gastric cancer (FACT).
TPS466 Background: Fruquintinib, an oral tyrosine kinase inhibitor targeting VEGF receptors (VEGFR)-1,2, and 3, was recent...
Patient characteristics, first-line treatments, and overall survival among locally advanced, unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma patients at a large academic medical center in the United States.
317 Background: Patients diagnosed with advanced-stage gastric and gastroesophageal junction cancer (adv GC/GEJC) represen...
BREAKWATER phase 3: Post hoc subgroup analyses by age in patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC).
122 Background: Most mCRC occurs in pts ≥50 y old but increasingly pts <50 y are being diagnosed with mCRC. Evidence re...
Quantification of circulating tumor DNA (ctDNA) using a methylation-based, tissue-free colorectal cancer (CRC) test for the detection of molecular residual disease (MRD).
217 Background: MRD detection by measuring ctDNA has been shown to predict disease recurrence. We have previously demonstr...
Stereotactic body radiotherapy for resectable pancreatic ductal adenocarcinoma in patients unfit for surgical resection: A single-institution experience.
715 Background: Approximately 1 in 5 patients with pancreatic ductal adenocarcinoma (PDAC) present with surgically resecta...